▶ BPC-157 · SUBTOPIC · DOSING LITERATURE
BPC-157 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of BPC-157. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for BPC-157 reports the following route(s) of administration: Subcutaneous, Intraperitoneal, Oral (animal studies). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of BPC-157.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for BPC-157 of approximately ~4 hours (rat, intraperitoneal). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of BPC-157. Refer to the original publication for full protocol detail.
- Sikiric P, Sever M, Krezic I, et al. (2024) reports the BPC-157 protocol used in New studies with stable gastric pentadecapeptide protecting gastrointestinal tract, published in Inflammopharmacology. PMID 38980576. See the source for the protocol-level dose range, frequency, and duration. link
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P (2006) reports the BPC-157 protocol used in Achilles detachment in rat and stable gastric pentadecapeptide BPC 157, published in J Orthop Res. PMID 16583442. See the source for the protocol-level dose range, frequency, and duration. link
- Staresinic M, Sebecic B, Patrlj L, et al. (2006) reports the BPC-157 protocol used in Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157, published in J Orthop Res. PMID 16609979. See the source for the protocol-level dose range, frequency, and duration. link
- Matek D, Matek I, Japjec M, et al. (2026) reports the BPC-157 protocol used in Tendon, Ligament, and Muscle Injury · Cytoprotection Review with BPC 157, published in Pharmaceuticals (Basel). PMID 41754849. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is the half-life of BPC-157?
Animal studies report a plasma half-life around 4 hours after intraperitoneal administration. The peptide is also reported to remain stable in human gastric juice for over 24 hours, which is unusual and theorized to underpin oral activity in animals.
▶ Can BPC-157 be taken orally?
Animal studies show oral and drinking-water routes preserve activity, attributed to the unusual gastric-juice stability. Human oral bioavailability has not been characterized in clinical trials.
▶ How long do you cycle BPC-157 in animal studies?
Published animal-model protocols typically span 2–8 weeks of daily administration. Community-reported research protocols cite 8–12 week cycles, though those are not clinical recommendations.
▶ How is BPC-157 stored?
Lyophilized BPC-157 is stable at 4 °C for at least 24 months and indefinitely at −20 °C. Reconstituted solution should be stored at 2–8 °C and used within 28 days. Do not freeze the reconstituted solution.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months, −20 °C indefinite
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A. Not FDA-approved for any human use.
WADA · Prohibited at all times (in-competition and out-of-competition) under S0 'non-approved substances' since the 2022 Prohibited List.
RELATED PAGES
▶ LAST UPDATED · 2026-05-19